$TDSGF: NEWS........ Patents awarded
Now 0.1455
GO $TDSGF
********************************************************
Telo Genomics Announces the Final Assignment of Patents on Hematological Cancers, Liquid Biopsy and Alzheimer's Disease
TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the "Company" or "TELO") is pleased to announce that it has received final approval and grant of three of its pending patent applications including: -- Diagnostic Methods for Hematological Disorders (Hematological Cancers) - Canada -- Methods for Characterizing and isolating circulating tumor cell subpopulations (Liquid biopsy) - Canada -- Methods of Diagnosing Alzheimer's Disease - Europe TELO has already been granted final patents governing its intellectual property ("IP") for hematological cancers in the USA, and Alzheimer's Disease in the USA and Canada. TELO's patent application on liquid biopsy in the USA is still pending. TELO has secured intellectual property protection in various jurisdictions around the world and owns a portfolio of patents and pending patent applications in the United States, Canada and the EU. The scope of the IP covers its core technology and specific applications of the technology. In addition to the patents and pending patent applications, TeloView(R) is protected as a trademark in the USA, Canada, Europe and Israel. "The issuance of three additional final patents further augments TELO's already strong IP portfolio," said Sabine Mai, TELO Director, and Chair of the Clinical and Scientific Advisory Board. "Blood cancers and liquid biopsy are at the core of the Company's commercialization program. The issuance of these patents assures the long-term protection of the TeloView(R) platform as a prognostic/diagnostic tool for these diseases."
